Background The role of bortezomib in the treatment of immunoglobulin light chain (AL)
amyloidosis is not well defined. We performed this meta-analysis to evaluate the efficacy …

Introduction: Chemotherapeutic options for patients with systemic light chain amyloidosis
(AL) who are not transplant candidates include bortezomib based therapy, melphalan with …

Introduction Before 2021, the combination of bortezomib, cyclophosphamide, and
dexamethasone (VCd) was one of the most used upfront therapy for systemic …

In immunoglobulin light-chain (AL) amyloidosis, the depth of hematologic response to
treatment is associated with improved survival and organ responses. We conducted a …

Rarity of light-chain amyloidosis (AL) makes randomized studies challenging. We pooled
three phase II studies of immunomodulatory drugs (IMiDs) to update survival, toxicity, and …

Year of initiation of trial 2004 2008 2012 Median age, years (range) 62 (40-82) 70 (57-84)
68 (44-79) 67 Male/female 52/30 5/11 16/11 73/52 Cardiac involvement (%) 41 (50%) 11 …

Introduction: There are a lack of randomized trials to guide therapy for relapsed AL
amyloidosis with treatment regimens generally extrapolated from experience in multiple …

Bortezomib combination chemotherapy appears to be active in light chain (AL) amyloidosis
with high rates of hematologic and organ response. We report a retrospective evaluation of …

Bortezomib began to be used in the treatment of light chain (AL) amyloidosis in recent years.
We performed the first meta-analysis of randomized clinical trials and clinical controlled trials …

Background Treatment protocols for light chain (AL) amyloidosis have been derived from
myeloma treatment. Bortezomib is a key drug used for the treatment of myeloma and AL …